Evidence map›Paper›PMID 41741970›Full record

ArticleVeterinary and comparative oncology2026

CD30 Expression in Neoplastic Mast Cells and the Presence of CD30+, CD3+, and PAX-5+ Tumour-Infiltrating Lymphocytes as Prognostic Markers in Canine Cutaneous Mast Cell Tumours.

Fernanda Ramalho Ramos, Janayna Maria Parente Serafim, Bethânia Almeida Gouveia, Pedro Luiz Porfirio Xavier, Juliano Rodrigues Sangalli, Heidge Fukumasu, Ricardo de Francisco Strefezzi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Veterinary and comparative oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fernanda Ramalho RamosLaboratory of Comparative and Translational Oncology, Department of Veterinary Medicine, School of Animal Science and Food Engineering, University of São Paulo, Pirassununga, Brazil.ORCID https://orcid.org/0000-0002-7972-6482
Janayna Maria Parente SerafimLaboratory of Comparative and Translational Oncology, Department of Veterinary Medicine, School of Animal Science and Food Engineering, University of São Paulo, Pirassununga, Brazil.ORCID https://orcid.org/0000-0002-1181-4291
Bethânia Almeida GouveiaLaboratory of Comparative and Translational Oncology, Department of Veterinary Medicine, School of Animal Science and Food Engineering, University of São Paulo, Pirassununga, Brazil.ORCID https://orcid.org/0000-0001-5378-4222
Pedro Luiz Porfirio XavierLaboratory of Comparative and Translational Oncology, Department of Veterinary Medicine, School of Animal Science and Food Engineering, University of São Paulo, Pirassununga, Brazil.ORCID https://orcid.org/0000-0002-2435-9822
Juliano Rodrigues SangalliDepartment of Veterinary Medicine, School of Animal Science and Food Engineering, University of São Paulo, Pirassununga, Brazil.ORCID https://orcid.org/0000-0002-4410-2506
Heidge FukumasuLaboratory of Comparative and Translational Oncology, Department of Veterinary Medicine, School of Animal Science and Food Engineering, University of São Paulo, Pirassununga, Brazil.ORCID https://orcid.org/0000-0002-3265-5090
Ricardo de Francisco StrefezziLaboratory of Comparative and Translational Oncology, Department of Veterinary Medicine, School of Animal Science and Food Engineering, University of São Paulo, Pirassununga, Brazil.ORCID https://orcid.org/0000-0002-8810-2815

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 303748/2021-4Fundação de Amparo à Pesquisa do Estado de São Paulo 2020/10582-0Fundação de Amparo à Pesquisa do Estado de São Paulo 2022/06305-7Fundação de Amparo à Pesquisa do Estado de São Paulo 2022/09378-5Fundação de Amparo à Pesquisa do Estado de São Paulo 2023/00296-9Fundação de Amparo à Pesquisa do Estado de São Paulo 2023/05099-7
6 · The paper itself

Abstract

Canine cutaneous mast cell tumour (MCT) is the most common skin neoplasm in dogs, with histopathology serving as both the diagnostic and primary prognostic tool. However, identifying reliable biomarkers is essential for improving clinical decision-making. CD30, a member of the TNF receptor superfamily, is well-characterised in human haematopoietic malignancies. However, its role in canine MCTs remains unclear. This study aimed to evaluate CD30 expression in neoplastic mast cells and tumour-infiltrating lymphocytes (TILs), and to assess its prognostic significance in canine cutaneous MCTs. Immunohistochemical analysis of CD30, CD3, and PAX-5 was performed on 53 samples, and RNA sequencing was conducted to assess CD30 transcript levels in 17 cases. CD30 was detected in 94.6% of neoplastic mast cells, with strong staining observed in 35 cases and weak staining in 18. Strong CD30 expression (p = 0.0051), CD30+ TIL counts (p = 0.0105) and the diffuse infiltrate distribution pattern of CD3+ TILs (p = 0.0497) were associated with shorter post-surgical survival. RNA sequencing confirmed higher CD30 (TNFRSF8) gene expression levels in high-risk tumours (logFC = 2.3182; FDR = 0.0405). These findings suggest that CD30 is a promising biomarker with potential prognostic value in canine cutaneous MCTs.

Indexed as

Dog DiseasesKi-1 AntigenLymphocytes, Tumor-InfiltratingMast CellsSkin NeoplasmsAnimalsBiomarkers, TumorCD3 ComplexDogsFemaleGene Expression Regulation, NeoplasticMalePAX5 Transcription FactorPrognosisBiomarkers, TumorCD3 ComplexKi-1 AntigenPAX5 Transcription Factorcancerimmunohistochemistrymast cellsprognosisTNFRSF8

Identifiers

PMID41741970
PMCPMC13161744

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.